

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/780,990 02/09/2001		02/09/2001	Richard H. Peters	8500-0258	2254	
23980	7590	03/21/2003				
REED & E	BERLE I	LLP	EXAMINER			
800 MENLO AVENUE, SUITE 210 MENLO PARK, CA 94025				QAZI, SAB	QAZI, SABIHA NAIM 12	
				ART UNIT	PAPER NUMBER	
				1616		
			DATE MAILED: 03/21/2003			

Please find below and/or attached an Office communication concerning this application or proceeding.

	A south and a south	A !! + (! -)					
•	Application No.	Applicant(s)					
Office Action Summany	09/780,990	PETERS ET AL.					
Office Action Summary	Examiner	Art Unit					
TI MAN INC DATE of this comment of the	Sabiha Naim Qazi	1616					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1) Perpensive to communication(s) filed on 02.5	Jacombor 2002						
1) Responsive to communication(s) filed on <u>02 D</u>							
<u> </u>	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) <u>1-16 and 18-44</u> is/are pending in the	4) Claim(s) 1-16 and 18-44 is/are pending in the application.						
4a) Of the above claim(s) 1-13,19,20,22-36,38-40 and 42-44 is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.	Claim(s) is/are allowed.						
6) Claim(s) <u>14-16, 18, 21, 37 and 41</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) ratent Application (PTO-152)					

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 09/780,990

Art Unit: 1616

Acknowledgement is made of the response and amendment filed in paper no. 11.

Amendments are entered. Claims 1-16 and 18-44 are pending. Claims 1-13, 19, 20,22-36, 38, 39, 40, 42-44 are withdrawn from consideration as non-elected invention. Claims 14-18, 21, 37 and 41 are rejected. Rejections under 102 and 112 are withdrawn because claims are amended. Double Patenting rejection is maintained because no terminal disclaimer was filed.

Applicant's arguments do not comply with 37 CFR 1.111(c) because they do not clearly point out the patentable novelty which he or she thinks the claims present in view of the state of the art disclosed by the references cited or the objections made.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

Art Unit: 1616

2. Ascertaining the differences between the prior art and the claims at issue.

3. Resolving the level of ordinary skill in the pertinent art.

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claim 14-16, 18 21, 37 and 41 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Tanabe et al. (WO 99/33859). Tanabe et al teach anti-estrogenic steroids, their compositions and method of use which embraces presently claimed invention. See the entire document especially, compound of formula 1b on page 23; preferred compound of formula IIIb on page 25; compounds listed on page 32, 33, 34, 35, and 37; scheme 16 and compound 79; scheme 17 and compounds 81, 82, 83 and 84.

Presently claimed invention differs from the reference in claiming the selective compounds from prior art invention.

Scheme 16

Application/Control Number: 09/780,990

Art Unit: 1616

Scheme 17

See compounds on page 32.

It would have been obvious to one skilled in the art to prepare additional beneficial compounds for medicinal use because prior art teaches such compounds. Motivation is that these anti-estrogenic steroids are taught to be useful for block of binding of estrogen to its receptor.

In the light of the forgoing discussion, the Examiner's ultimate legal conclusion is that the subject matter defined by the instant claims would have been obvious within the meaning of 35 U.S.C. 103(a).

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be

Application/Control Number: 09/780,990

Art Unit: 1616

calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sabiha Naim Qazi whose telephone number is 703-305-3910. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees can be reached on 703-308-4628.

The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

SABIHA QAZI, PH.D PRIMARY EXAMINER

March 21, 2003

Page 5